US equities |
MU $1,074.89 ▲+0.00% INTC $119.13 ▼-0.17% NVDA $233.95 ▲+0.00% META $728.08 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% SPCX $158.96 ▲+0.00% PTC $144.03 ▲+0.00%
FinancialContent

Articles published by Rhythm Pharmaceuticals, Inc.

< Previous 1 2 3 4 5 Next >
News headline image
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Changes to Board of Directors
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
News headline image
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
From Rhythm Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers RYTM
< Previous 1 2 3 4 5 Next >